share_log

Biofrontera (NASDAQ:BFRI) Trading Down 1.1%

Biofrontera (NASDAQ:BFRI) Trading Down 1.1%

生物弗龍特拉 (納斯達克:週五) 交易下跌 1.1%
Defense World ·  2022/12/27 02:01

Biofrontera Inc. (NASDAQ:BFRI – Get Rating) fell 1.1% on Monday . The stock traded as low as $0.91 and last traded at $0.93. 3,094 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,218,819 shares. The stock had previously closed at $0.94.

納斯達克(BFRI-GET)週一下跌1.1%。該股交易價格低至0.91美元，最後報0.93美元。午盤成交量為3,094股，較1,218,819股的平均日成交量下降100%。該股此前收盤價為0.94美元。

Biofrontera Stock Performance

Biofrontera股票表現

The stock has a fifty day moving average price of $1.01 and a 200-day moving average price of $1.29. The firm has a market cap of $24.83 million, a PE ratio of -0.82 and a beta of 1.12.

該股的50日移動均價為1.01美元，200日移動均價為1.29美元。該公司市值為2483萬美元，本益比為-0.82，貝塔係數為1.12。

Get
到達
Biofrontera
生物翅目
alerts:
警報：

Biofrontera (NASDAQ:BFRI – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.09. Biofrontera had a negative net margin of 44.62% and a negative return on equity of 113.65%. The firm had revenue of $4.32 million for the quarter, compared to analysts' expectations of $4.32 million. As a group, equities analysts predict that Biofrontera Inc. will post -0.92 earnings per share for the current fiscal year.

納斯達克(BFRI-GET Rating)上一次公佈季度收益是在11月14日(星期一)。該公司公佈本季度每股收益(0.23美元)，比分析師普遍預期的(0.32美元)高出0.09美元。Biofrontera的淨利潤率為負44.62%，淨資產回報率為負113.65%。該公司當季營收為432萬美元，高於分析師預期的432萬美元。股票分析師預計，作為一個整體，Biofrontera Inc.本財年每股收益將達到0.92美元。

Institutional Trading of Biofrontera

生物前翅目昆蟲的制度性交易

Several large investors have recently added to or reduced their stakes in BFRI. State Street Corp lifted its stake in shares of Biofrontera by 55.8% during the second quarter. State Street Corp now owns 22,900 shares of the company's stock worth $43,000 after purchasing an additional 8,200 shares in the last quarter. Bard Associates Inc. lifted its position in Biofrontera by 5.4% during the 2nd quarter. Bard Associates Inc. now owns 259,275 shares of the company's stock worth $482,000 after acquiring an additional 13,200 shares in the last quarter. XTX Topco Ltd purchased a new position in Biofrontera in the 1st quarter worth approximately $48,000. Northern Trust Corp acquired a new stake in Biofrontera in the second quarter valued at approximately $39,000. Finally, BlackRock Inc. grew its position in Biofrontera by 894.0% in the first quarter. BlackRock Inc. now owns 100,505 shares of the company's stock valued at $335,000 after acquiring an additional 90,394 shares in the last quarter. 6.84% of the stock is currently owned by institutional investors and hedge funds.
幾家大型投資者最近增持或減持了BFRI的股份。道富銀行在第二季度增持了Biofrontera的股份55.8%。道富銀行目前持有22,900股該公司股票，價值43,000美元，此前該公司在上個季度又購買了8,200股。Bard Associates Inc.在第二季度將其在Biofrontera的頭寸提高了5.4%。Bard Associates Inc.現在持有259,275股該公司股票，價值482,000美元，該公司在上個季度又收購了13,200股。XTX Topco Ltd在第一季度購買了Biofrontera的一個新頭寸，價值約48,000美元。北方信託公司在第二季度收購了Biofrontera的新股份，價值約3.9萬美元。最後，貝萊德股份有限公司在第一季度將其在Biofrontera的頭寸增加了894.0%。貝萊德股份有限公司在上個季度增持了90,394股後，現在持有100,505股該公司股票，價值335,000美元。6.84%的股票目前由機構投資者和對沖基金持有。

Biofrontera Company Profile

Biofrontera公司簡介

(Get Rating)

(獲取評級)

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.

Biofrontera Inc是一家生物製藥公司，在美國從事治療皮膚病的藥物產品的商業化。該公司提供處方藥Ameluz和用於光動力療法的RhodoLED燈系列，用於面部和頭皮輕至中度光化性角化病的病變導向和視野導向治療。

Read More

閱讀更多內容

  • Get a free copy of the StockNews.com research report on Biofrontera (BFRI)
  • Three Healthcare Penny Stocks to Watch In The New Year
  • Southwest Airlines Stock, There is a Lot to Love
  • MarketBeat: Week in Review 12/19 – 12/23
  • These Steelmakers Deserve A Place On Your 2023 Watch List
  • Inflation Cools, Where Does The S&P 500 Go Now
  • 免費獲取StockNews.com關於生物前翅目(BFRI)的研究報告
  • 新年值得關注的三隻醫療保健便士股
  • 西南航空公司股票，有很多值得愛的東西
  • MarketBeat：回顧一週12/19-12/23
  • 這些鋼鐵制造商理應在2023年觀察名單上佔有一席之地
  • 通脹降溫，標普500指數何去何從

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Biofrontera Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Biofrontera和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論